Moderna Inc. saw a notable increase in its stock price, driven by renewed interest in cancer vaccine partnerships and upcoming earnings.
Moderna Inc. (NASDAQ:MRNA) experienced a solid gain of 4.65% in its stock price yesterday, closing at CA$226.30. This uptick comes as the company garners renewed interest in its cancer vaccine initiatives and prepares for its Q3 2026 earnings update.
Advertisement
Moderna Inc
MRNA.US
MRNA.US
Moderna Inc
WealthAwesomeMarket cap
$94.42B
52W high
$242.29
52W low
$22.28
1W change
+20.05%
Beta
1.09
Analyst Price Targets
Based on 23 analysts covering MRNA · as of Oct 16, 2026
Wall Street analysts forecast MRNA stock price to fall 47.7% over the next 12 months.
Consensus
Hold3.17 / 5.00
Avg. Target
C$123.61
-47.7% Upside
Previously C$122.67 on Oct 12, 2026
Current Price
C$236.50
Last close
Analyst Breakdown (23 analysts)
Targets are snapshotted when they change. Unchanged figures keep their original date. Not financial advice.
Wealth Awesome Price Forecast
WA ModelStatistical 90-day price range based on MRNA's historical volatility
30-Day Vol
78.5%
Annualized
90-Day Vol
194.3%
Annualized
Trend (90d)
+50.0%
Annualized drift
90d Mean
C$282.74
Expected price
| Horizon | Expected | 68% Range (1σ) |
|---|---|---|
| 30 trading days | C$251.00 | C$191.43 – C$329.12 |
| 60 trading days | C$266.40 | C$181.60 – C$390.80 |
| 90 trading days | C$282.74 | C$176.83 – C$452.07 |
Methodology: Range is calculated using 30-day realized volatility via geometric Brownian motion (log-normal model). 68% band = ±1σ, 95% band = ±2σ. This is a statistical model, not a prediction. Past volatility does not guarantee future results. Not financial advice.
Advertisement
Investor takeaway: Investors are optimistic about Moderna's potential in the oncology space, particularly following positive developments in its cancer vaccine research.
4.65%
Moderna's stock price rose by 4.65%, adding to its recent gains and reflecting investor optimism.
Bull case
The recent rise in stock price shows that investors are gaining confidence in Moderna's cancer vaccine partnerships and its innovative mRNA technology. This technology could lead to significant revenues in the future.
Bear case
Despite the positive momentum, investors should stay cautious as competition in the oncology market heats up. The company needs to show continued clinical success to keep this growth going.
Renewed Interest in Cancer Vaccines
Advertisement
Moderna's recent stock performance has been significantly influenced by renewed interest in its cancer vaccine partnerships. The company is advancing its personalized mRNA-based cancer therapy, intismeran autogene, which has shown promising results in clinical trials. This has attracted attention from investors looking for growth opportunities in the oncology sector.
Upcoming Q3 Earnings Update
Investors are eagerly awaiting Moderna's Q3 2026 earnings update, which is expected to provide insights into the company's financial health and progress in its cancer vaccine initiatives. The anticipation surrounding the earnings report could further influence stock performance, depending on the results and management's outlook.
Competitive Landscape and Future Prospects
While Moderna's recent gains are encouraging, the company faces stiff competition in the oncology market from rivals developing similar therapies. Investors should keep an eye on how Moderna navigates this competitive landscape and whether it can sustain its growth trajectory through successful clinical outcomes and market expansion.
Best next step
Keep exploring this topic
If you want to go deeper, these are the most useful follow-up pages and tools for this topic.
Broker comparison
Best trading platforms in Canada
Compare $0-commission brokers before you act on a ticker story.
Safe cash
Best GIC rates in Canada
If the story makes you want to de-risk, compare guaranteed rates next.
HISA roundup
Best high-interest savings accounts
Keep dry powder in a no-fee savings account instead of chequing.
TFSA room
Check TFSA contribution room
Shelter the next contribution before you buy.
Advertisement
Wealth Awesome
Timely coverage of Canadian stocks, earnings, dividends, and market movers for DIY investors. Stories are checked against exchange data and public filings.
View Full Profile →✅ Reviewed by Certified Financial Professionals
This content has been reviewed by CFA® charterholders and Certified Financial Planners (CFP®) with over a decade of experience in Canadian financial markets. All information is fact-checked against official Canadian sources and regulations.
Why these credentials matter: CFA® charterholders complete 900+ hours of rigorous study in investment analysis and ethics. CFP® professionals are held to the highest standards of financial planning competency and fiduciary duty in Canada.
⚠️ Professional Disclaimer
This content is for educational purposes only and should not be considered personalized financial advice. While our team brings professional expertise, individual circumstances vary. For personalized guidance, consult with a qualified financial advisor, tax professional, or mortgage specialist.
